Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)

Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders

Volumn 4, Issue 3, 2003, Pages 191-206

  Miller, Robert G ^a   Mitchell, J D ^b   Lyon, M ^c   Moore, D H ^a  

^a CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^b ROYAL PRESTON HOSPITAL   (United Kingdom)

^c The ALS Association National Office   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; HEMOGLOBIN; PLACEBO; RILUZOLE;

ADULT; AMYOTROPHIC LATERAL SCLEROSIS; ANOREXIA; ARTIFICIAL VENTILATION; ASTHENIA; CLINICAL TRIAL; COCHRANE LIBRARY; COMPUTER PROGRAM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; HAZARD ASSESSMENT; HEALTH STATUS; HUMAN; INFORMATION PROCESSING; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MEDICAL EXPERT; META ANALYSIS; METHODOLOGY; MORTALITY; MOTOR NEURON DISEASE; MUSCLE STRENGTH; NAUSEA AND VOMITING; NEUROMUSCULAR FUNCTION; PARESTHESIA; PRIORITY JOURNAL; PROBABILITY; QUALITY CONTROL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SURVIVAL; TRACHEOSTOMY; TREATMENT OUTCOME; VERTIGO;

ADULT; AMYOTROPHIC LATERAL SCLEROSIS; DATABASES; DOUBLE-BLIND METHOD; DRUG EVALUATION; HUMANS; MOTOR NEURON DISEASE; MULTICENTER STUDIES; MUSCLES; NEUROPROTECTIVE AGENTS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS; RILUZOLE; RISK; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 0141614827     PISSN: 14660822     EISSN: None     Source Type: Journal    
DOI: 10.1080/14660820310002601     Document Type: Review

References (34)

1. McGuire D, Garrison L, Miller RG. Relationship of the Tufts Quantitative Neuromuscular Exam (TQNE) and the Sickness Impact Profile (SIP) in measuring progression of ALS. Neurology 1996; 46: 1442-1444.
2. Rothstein JD. Therapeutic horizons for amyotrophic lateral sclerosis. Current Opinion in Neurobiology 1996; 6: 679-87.
3. Bensimon G, Lacomblez L, Meininger V and the Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet 1996; 347: 1425-31.
4. Rowland LP. Riluzole for the treatment of amyotrophic lateral sclerosis: too soon to tell? New England Journal of Medicine 1994; 330: 636-7.
5. Lacomblez L, Bensimon G, Leigh PN et al. The Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet 1996; 347: 1425-31.
6. Bensimon G, Lacomblez L, Delumeau JC, Bejuit R, Truffinet P, Meininger V. Riluzole/ALS Study Group II. A study of riluzole in the treatment of advanced stage or elderly patients with amyotrophic lateral sclerosis. J Neurol. 2002;249:609-15.
7. Yanagisawa N, Tashiro K, Tohgi H et al. Efficacy and safety of riluzole in patients with amyotrophic lateral sclerosis: double-blind placebo-controlled study in Japan. Igakuno Ayumi 1997; 182: 851-866.
8. Quality Standards Subcommittee of the American Academy of Neurology. Practice advisory on the treatment of amyotrophic lateral sclerosis with riluzole. Neurology 1997; 49: 657-659.
9. Hugon J. Riluzole and ALS therapy. Weiner Medizinische Wochenschrift 1996; 146: 185-7.
10. Hugon J. ALS therapies: targets for the future. Neurology 1996; 47: S251-4.
11. Miller RG, Bouchard JP, Duquette P et al. Clinical trials of riluzole in patients with amyotrophic lateral sclerosis. Neurology 1996; 47(suppl 2): S86-S92.
12. Wokke J. Riluzole. Lancet 1996; 348: 795-799.
13. Meininger V, Dib M, Aubin F et al. The Riluzole Early Access Programme: descriptive analysis of 344 patients in France. ALS/Riluzole Study Group III. Neurology 1997; 244 (suppl 2): S22-5.
14. Chilcott J, Golightly P, Jefferson D et al. The use of riluzole in the treatment of amyotrophic lateral sclerosis. Working Group on Acute Purchasing. Trent Institute for Health Services Research, Universities of Leicester, Nottingham and Sheffield 1997.
15. Booth-Clibborn N, Best L, Stein K. Riluzole for motor neurone disease. In: Southampton: Wessex Institute for Health Research & Development (DEC Report 73). Southampton, 1997.
16. Committee for Proprietary Medicinal Products. European Public Assessment Report (EPAR) Rilutek. The European Agency for the Evaluation of Medicinal Products 1997 (CPMP/290/296).
17. National Institute for Clinical Excellence. Guidance on the use of riluzole (Rilutek) for treatment of motor neurone disease. Technology Appraisal Guidance 2001; 20.
18. Stewart A, Sandercock J, Bryan S et al. The clinical effectiveness and cost-effectiveness of riluzole for motor neurone disease. In: Health Technology Assessment: West Midlands Dev. & Assess. Svce. University of Birmingham, 2000.
19. Meininger V, Lacomblez L, Salachas F. What has changed with riluzole? Journal of Neurology 2000; 247: 19-22.
20. Traynor BJ, Alexander M, Corr B et al. Riluzole and prognosis in ALS: findings of the Irish ALS register over a five year study period. Amyotrophic lateral sclerosis and other motor neuron disorders 2001; 2 (suppl 2): 43-44.
21. Turner MR, Bakker M, Sham P et al. The Kings' Database 1990-2000: an analysis of the effect on survival of interventions in amyotrophic lateral sclerosis. Amyotrophic lateral sclerosis and other motor neuron disorders 2001; 2 (suppl 2): 43.
22. Parmar MKB, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 1998; 17: 2815-2834.
23. Lacomblez L, Bouche P, Bensimon G, Meininger V. A double-blind, placebo-controlled trial of high doses of gangliosides in amyotrophic lateral sclerosis. Neurology 1989; 39: 1635-7.
24. Riviere M, Meininger V, Zeisser P, Munsat T. An analysis of extended survival in patients with amyotrophic lateral sclerosis treated with riluzole. Archives of Neurology 1998; 55: 526-528.
25. Stambler N, Charatan M, Cedarbaum J and the ALS CNTF Treatment Study Group. Prognostic indicators of survival in ALS. Neurology 1998; 50: 66-72.
26. Sojka P, Anderson PM, Forsgren L. Effects of riluzole on symptom progression in amyotrophic lateral sclerosis. Lancet 1997; 349: 176-177.
27. Riviere M, Meininger V, Zeisser P, Munsat T. An analysis of extended survival in patients with amyotrophic lateral sclerosis treated with riluzole. Archives of Neurology 1998; 55: 526-528.
28. Kalra S, Cashman NR, Genge A, Arnold DL. Recovery of N-acetylaspartatc in corticomotor neurons of patients with ALS after riluzole therapy. Neuroreport 1998; 9: 1757-1761.
29. Arriada-Mendicoa N, Otero-Silicco E, Burbano G, Corona-Vazquez T. Open label study of riluzole for the treatment of amyotrophic lateral sclerosis. Revista Ecuatoriana de Neurologia 1999; 8: 33-36.
30. Pongratz D, Neundorfer B. Open-label trial of riluzole 50 mg b.i.d. in treatment of amyotrophic lateral sclerosis (ALS). Aktuelle Neurologie 1999; 26: 225-229.
31. Desiato MT, Palmieri MG, Giacomini, Scalise A, Arciprete F, Caramia MD. The effect of riluzole in amyotrophic lateral sclerosis: a study with cortical stimulation. Journal of Neurological Sciences 1999; 31: 98-107.
32. Couratier P, Druet-Cabanac M, Truong CT, Bernet-Bernady P, Dumas M, Vallat JM, Preux PM. Interets d'une base de donnces informatisee dans ic diagnostic et lc suivi de patients atteints de la sclerose laterale amyotrophique Interest of a computerized ALS database in the diagnosis and follow-up of patients with ALS. Revue Neurologique 2000; 156: 357-363.
33. Brooks BR. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on motor neuron diseases/ALS of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial "Clinical limits of amyotrophic lateral sclerosis" workshop contributors. Journal of Neurological Sciences 1994; 124 (suppl): 96-107.
34. Miller RG, Rosenberg JA, Gelinas DF et al. Practice parameter: the care of the patient with amyotrophic lateral sclerosis (an evidence-based review). Neurology 1999; 52: 1311-1323.